Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I can see the possibilities...and I appreciate your sharing your thoughts on this.
I have been gone for a few weeks and it looks like this has consolidated nicely.
I'm going to dip my toe in, and hope that Management doesn't screw things up.
Bring on the Q!
:)
I noticed a ct order and read baker bros are dumping shares. I hope the are dumping lots of shares betting against cers could mean something about the execution of management. And y does it say pathogen reduction instead of pathogen inactivation on website now.......
I noticed a ct order and read baker bros are dumping shares. I hope they are not dumping lots of shares betting against cers could mean something about the execution of management. And y does it say pathogen reduction instead of pathogen inactivation on website now.......
Knock your socks off article why CERS is so valuable. Article is NOT a direct call for CERS. It allows the reader to understand what positive effect will happen, when a nation that currently has only 1/3 blood supply on hand and only critical surgery allowed, if pathogen inactivation is used. Disease is being spread by transfusion, forcing contributions to only 1% of population. Blood is being sold at $160/100cc (.2 pint). CERS could cure the problem in months not decades. The potential for Cerus is enormous. http://www.cnbc.com/id/102427075
Ooops, Feb 26 after the close.
Q4 report should be around Feb. 24, 2015 but I am not sure. Anyone got the date/time?
IntRAday (within that one day) has hit momentarily below $5 but recovered well. I do not see it (without good factual reason) going under $5 intERday for a period of time. There have been a set of about 400,000 share shorts that have taken about 6 weeks to complete. Those have effected the $7 potential that was axed (nearly simultaneously) by the 12+million shares floated by CERS officers. Until the float gets fully bought and the additional shares cashed by the handlers (Cowan et al) I see a stall in the price. However, barring some other CERS officio making a doo-doo of the stock and the Q4 report at least neutral, there is a good reason to see the stock rise toward the $10 area of the spectrum. 2015 should be the year it all comes together. With plasma, platelets, red blood cells and whole red blood being deactivated of pathogens, acclaimed by the World Health Organization and garnering FDA kudos, the time is long past for a vertical upswing...... as I said, it will be like a rocket. There is no deadline for take off and anyone trying to time it is dead, when the short fuse is lit. Buy large and sit still.
Where do you guys think this will bottom out?
5$ or will it drift down to 4.50?
I'm still watching...
looking for a good place to buy...
Yes they definitely need the money, My guess would be a dip in the AM and a move back up in the afternoon. Investors panic as soon as they see any sign of dilution. Eventually they start to look at the bigger picture.
Should be interesting to see if it is a dip or a plunge. Holding at $6 and later in the week a rise would be my expectation but that is up to the market forces. CERS certainly needs the marketing dollars if the product becomes a standard of care. Sales could be ok but fulfillment could be a catastrophe without the money to build the pipeline all over the world...... fast.
Cerus Announces Proposed Public Offering of Common Stock
http://finance.yahoo.com/news/cerus-announces-proposed-public-offering-210100066.html
Cerus Reports EU Phase 3 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint
http://finance.yahoo.com/news/cerus-reports-eu-phase-3-124500510.html?soc_src=mediacontentstory&soc_trk=tw
Got me another bargain nin buy
Yup however it was a blood red day overall for all stocks. Ironically the few OTC stocks I hold were up. Good time to get some cheaper shares. Just picked up 150 more shares.
Nope. As is typical, many took their profits and ran for the door. That is cool by me.
Can we break $7.00 today? I sure hope so.
Maybe depends on if they need partners for expansion and marketing. I still don't c 100$ especially with interest rates going up in spring of 2015...
I would expect $30-$40 by April 2015, $70 by August and $100 by the end of 2015. All this is my personal speculation, not withstanding that my $80 price might be a corporate offer of $40 cash and a stock certificate value of about $40. Who knows? I felt it should have been well over $10 nearly three years ago but CERS just had to issue stock at $2.85 a share to amass a lump of phase 2 money and blew the stock off of its $5 value and derailed the trend toward the $10 mark. The move was correct but it shot the heck out of the forward inertia. It is certainly worth the hold and patience.
They might get bought out before then.
Yes Thanks I saw that. I wish we could get past that 6.80 hump
When do you expect it to hit $100?
USA red blood cells at successful phase 2 and Europe the red blood cells at phase 3 and going for CE.
I bought 4/21/09 a $1.08..... have stayed long and will sell at over $100. Yep, you heard correctly.
12/22/2014 08:31:06 AM EST
Cerus Corporation (NASDAQ: CERS) announced today that its Phase 2 clinical trial of red blood cells treated with the INTERCEPT Blood System met its primary endpoint, with preliminary analysis demonstrating that greater than 75 percent of treated red blood cells continued to circulate 24 hours following transfusion. The investigators plan to submit data from the study for presentation at an upcoming scientific congress.
"We are pleased with the results of this study, which support the future advancement of the INTERCEPT red blood cell program into a Phase 3 study in the United States," said Dr. Laurence Corash, Cerus' Chief Medical Officer. "The data from this study met recommended criteria for a successful red cell recovery study and demonstrate that INTERCEPT red cells behave similarly to untreated red cells when infused into healthy volunteers.?
The randomized, single-blind, controlled, multi-center Phase 2 clinical trial of the INTERCEPT red blood cell system evaluated 26 healthy subjects at two United States clinical trial sites. Each subject received two transfusions of the subject's own red blood cells, one INTERCEPT-treated, and the other a control not treated for pathogen inactivation. Red blood cell units were stored for 35 days prior to transfusion. The primary endpoint of the clinical trial, a mean INTERCEPT red blood cell recovery of greater than 75 percent at 24 hours post-transfusion, was met. The INTERCEPT red blood cells had a recovery of 83% compared to 85% for control red blood cells, and both INTERCEPT-treated and control red blood cells met the criteria for red blood cell recovery recommended by the U.S. Food and Drug Administration.
In Europe, Cerus recently completed a Phase 3 clinical study of the INTERCEPT red blood cell system in patients with acute anemia and plans to file for CE mark approval.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Any idea where we go from here now that we have the FDA Approvals? Perhaps a couple of contracts to be announced soon?
$CERS DD Notes ~ http://www.ddnotesmaker.com/CERS
bullish
quick trade
longer term still fine
good time to get in
$CERS recent news/filings
## source: finance.yahoo.com
Fri, 19 Dec 2014 14:52:45 GMT ~ US STOCKS-Wall Street little changed after two-day run
[Reuters - UK Focus] - U.S. stocks were little changed on Friday, after the Federal Reserve's most recent policy statement sparked the best two-day run for the benchmark S&P 500 in three years. The S&P had climbed 4.5 percent ...
read full: http://uk.finance.yahoo.com/news/us-stocks-wall-street-little-145245910.html
*********************************************************
Fri, 19 Dec 2014 10:56:00 GMT ~ 5:56 am Cerus: FDA approves intercept blood system for platelets
read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#cers
*********************************************************
Fri, 19 Dec 2014 00:43:15 GMT ~ FDA Approves INTERCEPT Blood System for Platelets
[at noodls] - Second U.S. Approval for Cerus' INTERCEPT Blood System Extends Pathogen Reduction to Platelet Components CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (NASDAQ:CERS) today announced that the U.S. ...
read full: http://www.noodls.com/view/7E06F6E516924B885FF526DC83C124DCEDDB36A1
*********************************************************
Fri, 19 Dec 2014 00:20:00 GMT ~ FDA Approves INTERCEPT Blood System for Platelets
[Business Wire] - Cerus Corporation today announced that the U.S. Food and Drug Administration has approved the INTERCEPT Blood System for platelets. The INTERCEPT platelet syste
read full: http://finance.yahoo.com/news/fda-approves-intercept-blood-system-002000252.html
*********************************************************
Wed, 17 Dec 2014 21:48:00 GMT ~ Equity markets surge...so many stories – where to begin?
read full: http://finance.yahoo.com/tumblr/blog-equity-markets-surge-so-many-stories-where-to-214818005.html
*********************************************************
$CERS charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$CERS company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/CERS/company-info
Ticker: $CERS
OTC Market Place: Not Available
CIK code: 0001020214
Company name: Cerus Corp.
Incorporated In: DE, USA
$CERS share structure
## source: otcmarkets.com
Market Value: $482,139,516 a/o Dec 18, 2014
Shares Outstanding: 78,269,402 a/o Oct 24, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001
$CERS extra dd links
Company name: Cerus Corp.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CERS/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CERS/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CERS+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CERS+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CERS+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CERS/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CERS/news - http://finance.yahoo.com/q/h?s=CERS+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CERS/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CERS/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CERS/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CERS/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CERS/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CERS/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CERS/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CERS/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CERS+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CERS
DTCC (dtcc.com): http://search2.dtcc.com/?q=Cerus+Corp.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Cerus+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Cerus+Corp.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CERS/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CERS
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CERS/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CERS/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CERS/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001020214&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CERS/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CERS/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CERS/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CERS/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CERS&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CERS
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CERS/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CERS+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CERS+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CERS
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CERS
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CERS+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CERS/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CERS+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CERS.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CERS
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CERS/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CERS/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CERS/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CERS/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CERS
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CERS
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CERS:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CERS
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CERS
$CERS DD Notes ~ http://www.ddnotesmaker.com/CERS
Yeah I've been in since 4.25. I actually had a boatload of shares a few months ago but got impatient and sold some. Obviously I wish I would of held more but that the way it goes.
Picked up a few more. It's all green that's what counts. Profit is profit.
Nice!
Wish I'd found this a wee bit earlier...
Now I'm wondering if I should buy now?
Or wait for the pull back?
Anyway...Congrats to those who were here earlier...
:)
Awsome news. Jumped in this morning. Gl all
FDA Approves INTERCEPT Blood System for Platelets
Second U.S. Approval for Cerus’ INTERCEPT Blood System Extends Pathogen Reduction to Platelet Components
http://finance.yahoo.com/news/fda-approves-intercept-blood-system-002000252.html
yea!!!!! this came 5 months ahead of schedule.. I hear red blood cells in europe look ok.. stay tuned
Answer hell no plasma and platelet approvallllll eeeeeeweeeeeeeeeeeeeeeeeeeeeeeeeee
Platelet approval I just bought back in on Mon time just right o freakin to the yea I'm in biatch lol
Has anyone looked at aftermarket today ip another 1.04, sitting at 7.20. Really, your going to sell??. Thanks Ill take them.
$CERS DD Notes ~ http://www.ddnotesmaker.com/CERS
bullish
$CERS recent news/filings
## source: finance.yahoo.com
Wed, 17 Dec 2014 12:26:34 GMT ~ Now it’s the Fed’s turn to pour grease on the market fire
read full: http://www.marketwatch.com/News/Story/Story.aspx?guid=F7B20B4A-8585-11E4-A78E-BEA9A2E85394&siteid=yhoof2
*********************************************************
Tue, 16 Dec 2014 22:36:00 GMT ~ 5:36 pm Cerus confirms FDA approval of INTERCEPT Blood System for plasma
read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#cers
*********************************************************
Tue, 16 Dec 2014 22:31:00 GMT ~ FDA Approves INTERCEPT Blood System for Plasma
[Business Wire] - Cerus Corporation today announced that the U.S. Food and Drug Administration has approved the INTERCEPT Blood System for plasma. The INTERCEPT plasma system is
read full: http://finance.yahoo.com/news/fda-approves-intercept-blood-system-223100497.html
*********************************************************
Fri, 21 Nov 2014 13:50:54 GMT ~ FDA Accepts IDE Supplement for INTERCEPT Blood System Treatment of Ebola Convalescent Plasma
[at noodls] - Under IDE, Cerus will initiate trial with Emory University Hospital, University of Nebraska Medical Center American Red Cross and America's Blood Centers will participate to expand inventory of Ebola convalescent ...
read full: http://www.noodls.com/view/9B2E6C1E44C377D61F66E2935053F63432A30918
*********************************************************
Fri, 21 Nov 2014 13:30:00 GMT ~ FDA Accepts IDE Supplement for INTERCEPT Blood System Treatment of Ebola Convalescent Plasma
[Business Wire] - Cerus Corporation today announced that the U.S. Food and Drug Administration has accepted Cerus’ clinical protocol to make the INTERCEPT Blood System for plasma available under an Investigational Device Exemption for treatment of convalescent plasma collected from Ebola disease survivors for passive immune therapy.
read full: http://finance.yahoo.com/news/fda-accepts-ide-supplement-intercept-133000868.html
*********************************************************
$CERS charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$CERS company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/CERS/company-info
Ticker: $CERS
OTC Market Place: Not Available
CIK code: 0001020214
Company name: Cerus Corp.
Incorporated In: DE, USA
$CERS share structure
## source: otcmarkets.com
Market Value: $374,127,742 a/o Dec 16, 2014
Shares Outstanding: 78,269,402 a/o Oct 24, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001
$CERS extra dd links
Company name: Cerus Corp.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CERS/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CERS/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CERS+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CERS+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CERS+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CERS/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CERS/news - http://finance.yahoo.com/q/h?s=CERS+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CERS/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CERS/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CERS/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CERS/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CERS/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CERS/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CERS/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CERS/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CERS+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CERS
DTCC (dtcc.com): http://search2.dtcc.com/?q=Cerus+Corp.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Cerus+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Cerus+Corp.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CERS/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CERS
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CERS/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CERS/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CERS/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001020214&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CERS/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CERS/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CERS/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CERS/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CERS&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CERS
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CERS/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CERS+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CERS+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CERS
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CERS
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CERS+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CERS/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CERS+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CERS.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CERS
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CERS/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CERS/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CERS/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CERS/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CERS
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CERS
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CERS:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CERS
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CERS
$CERS DD Notes ~ http://www.ddnotesmaker.com/CERS
U think I should em or sellllllllllllll
It hit a high of 6.42 after hours. I actually saw an ask of $10 at one point. Should make a nice move in the AM.
FDA Accepts IDE Supplement for INTERCEPT Blood System Treatment of Ebola Convalescent Plasma
http://finance.yahoo.com/news/fda-accepts-ide-supplement-intercept-133000868.html
Mathew Abraham ?@MathaiKuttan 7m7 minutes ago
@Investor666 $CERS - FDA approves Intercept system for pathogen reduction in plasma
I think that is a good move the way this has been moving. An FDA decision could come anytime now.
I've sold mist of my pennys plays put it all here
Baker Bros Invests more money in $CERS
http://ih.advfn.com/p.php?pid=nmona&article=64766972&symbol=CERS
And for good reason.... This is RED Blood cells not just the Plasma and Platelets.
12/09/2014 07:04:31 AM EST
By Targeted News Service
ALEXANDRIA, Va., Dec. 9 -- Cerus, Concord, California, has been assigned a patent (8,900,805) developed by Naheed Mufti, San Ramon, California, Anna Erickson, Richmond, California, and Anne North, Pleasant Hill, California, for the "quenching methods for red blood cell pathogen inactivation."
The patent application was filed on April 9, 2009 (12/936,763). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=89,00,805.PN.&OS=PN/89,00,805&RS=PN/89,00,805
Written by Balkishan Dalai; edited by Jaya Anand.
BD1209JA1209-1088772
MLV Raises Cerus Price Target As It's Gaining Traction With FDA And Blood Centers Ahead Of U.S. Approval
http://www.smarteranalyst.com/2014/12/02/mlv-raises-cerus-price-target-as-its-gaining-traction-with-fda-and-blood-centers-ahead-of-u-s-approval/
MY BEST STOCK IN MY PORTFOLIO HOLDING THIS BABY LONG TERM..
Bill Gates? The Africa study will take an added step — use of an experimental system by Cerus Corp. for inactivating viruses in blood.
Dr. Ada Igonoh, a doctor in Nigeria who got Ebola from a patient and recovered, expects to donate plasma and recruit others for the study.
"Survivors will be willing if they understand the goal," she said.
She and Brantly met with Gates to discuss the project earlier this month at an American Society of Tropical Medicine & Hygiene conference in New Orleans.
excerpted from..... http://www.cnbc.com/id/102197664
$CERS Should hear soon on announced submission of their protocol to apply INTERCEPT to the treatment of Ebola convalescent plasma. The 30 day mark to hear from FDA on IDE is Nov 21st from Oct 21st notification.
"For Ebola, we recently announced submission of our protocol to apply INTERCEPT to the treatment of Ebola convalescent plasma. Plasma collected from individuals who have recovered from Ebola virus disease contain antibodies against the virus, these antibodies that can help fight Ebola infections in the recipient of the transfused plasma. Convalescent plasma has demonstrated benefit in prior disease outbreaks, and is one of the few therapies immediately available for Ebola virus disease. It is of note that each of the surviving patients treated in the U.S. received convalescent plasma during the active phase of their disease. A concern associated with collection of convalescent plasma from recovered patients is that they may carry undetected pathogens due to prior exposure, and their history of travel to Africa make these individuals temporarily ineligible to donate blood under U.S. regulatory guidelines. We believe that INTERCEPT pathogen inactivation can provide a critical risk mitigation strategy by inactivating harmful organisms that may be present without impacting the anti-Ebola antibodies that the patient needs."
Whoops! Looks as if another 2 quarters will pass by before CERS gets a reprieve from the down side. A future languishing in the $3.80 to $4.00 zone...... if the Greenman does not offer another discounted round of self inflicted financing (floating more stock). I am long too. This stock will be more like a Tourette Syndrome (no malice meant to those afflicted). The longer this stock languishes the more vertical the climb to its future highs. It is definitely proving NOT an overnight success. I could not ask for a better type of investment... the wait will be worth the time. However, this is a painful vigil.
Missed again on estimates and a revision downward for yearly revenues. I am long on this stock and am not looking to sell, but at some point, the company needs to at least meet expectations - every time this stock seems to gain some traction, the company releases disappointing results which in turn drives the price down again.
Followers
|
42
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
329
|
Created
|
05/30/09
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |